A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy.

Vanaudenaerde, B M; Meyts, I; Vos, R; Geudens, N; De Wever, W; Verbeken, E K; Van Raemdonck, D E; Dupont, L J; Verleden, G M

Vanaudenaerde, B M; Meyts, I; Vos, R; Geudens, N; De Wever, W; Verbeken, E K; Van Raemdonck, D E; Dupont, L J; Verleden, G M.

Affiliation

Vanaudenaerde BM; Laboratory of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium.

Eur Respir J ; 32(4): 832-43, 2008 Oct.

Article in En | MEDLINE | ID: mdl-18827151

Subject(s)

Anti-Bacterial Agents/pharmacology; Azithromycin/pharmacology; Bronchiolitis Obliterans/drug therapy; Bronchiolitis Obliterans/etiology; Lung Transplantation/adverse effects; Lung Transplantation/methods; Macrolides/pharmacology; Anti-Inflammatory Agents/pharmacology; Bronchoalveolar Lavage; Humans; Interleukin-8/metabolism; Lung/drug effects; Lung/physiopathology; Research Design; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Bronchiolitis Obliterans / Lung Transplantation / Azithromycin / Macrolides / Anti-Bacterial Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Eur Respir J Year: 2008 Document type: Article

Fulltext

XML

PubMed Links

Search on Google